Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
| ▸ | METAP1 | P53582 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18735317 | 0.93 | METAP2 (0.32) | METAP2METAP1KMT2APOLB | |
| SCHEMBL18735318 | 0.90 | METAP2 (0.32) | METAP2METAP1 | |
| SCHEMBL18735072 | 0.86 | GAA (0.39) | METAP2METAP1KMT2APOLBCYP1A2 | |
| SCHEMBL18735323 | 0.85 | METAP2 (0.36) | METAP2METAP1 | |
| SCHEMBL18735056 | 0.85 | KMT2A (0.35) | METAP2METAP1KMT2APOLBCYP1A2 | |
| SCHEMBL18735360 | 0.83 | METAP2 (0.35) | METAP2METAP1 | |
| SCHEMBL18735055 | 0.82 | KMT2A (0.33) | METAP2METAP1KMT2APOLBCYP1A2 | |
| SCHEMBL18735315 | 0.79 | METAP2 (0.36) | METAP2METAP1 | |
| SCHEMBL18735341 | 0.78 | GAA (0.37) | METAP2METAP1KMT2APOLBCYP1A2 | |
| SCHEMBL18735339 | 0.77 | CYP1A2 (0.32) | METAP2METAP1KMT2APOLBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017060400-A1 | PROTECTED CARBOXYLIC ACID-BASED METABOLITES FOR THE TREATMENT OF DISESASES RELATED TO MITOCHONDRIAL DYSFUNCTIONS | NEUROVIVE PHARMACEUTICAL AB (SE) | 2017-04-13 | — | — | WO | disclosed |